What the research found

Researchers developed a new metric called the Width-Delay Index (WDI) that estimates insulin resistance using only glucose measurements from a standard oral glucose tolerance test (OGTT). Rather than requiring the labour-intensive steady-state plasma glucose (SSPG) test—currently considered the reference standard for assessing insulin resistance—WDI captures how glucose behaves during the 15–120 minute window of an OGTT by accounting for how wide, how delayed, and how low the glucose response is.

The study tested WDI in 32 people who had detailed OGTT glucose profiles (16 measurement points) alongside SSPG measurements. WDI correlated well with actual SSPG values and outperformed standard glucose metrics and common insulin-based indices like HOMA-IR and the Matsuda index. Importantly, when the researchers recalculated WDI using only the 5-point glucose sampling typical of routine clinical OGTTs, it retained most of its predictive power, suggesting practical applicability.

Why it matters for you

If you're optimising your metabolic health through diet, training, or hormonal interventions (TRT, peptides), you've likely ordered an OGTT to assess your glucose control. Currently, interpreting that test relies on fasting glucose, the 2-hour value, or insulin-derived estimates—all of which miss important information about how your glucose rises and falls. WDI offers a way to extract more insight from data you probably already have.

This is particularly relevant if you're tracking metabolic biomarkers over time. A simple glucose-only metric that doesn't require additional blood sampling or complex insulin measurements could become a practical addition to your monitoring routine. For instance, if you're experimenting with fasting protocols, sleep interventions, or resistance training to improve insulin sensitivity, WDI could theoretically give you a more granular read on whether those changes are working—without needing repeat SSPG testing.

That said, this remains early-stage work on a small cohort. Before WDI shows up on your OGTT report or becomes part of standard clinical practice, it needs validation in larger and more diverse populations.

Caveats

• Very small sample size (32 subjects); findings require replication in larger groups
• Developed and tested on the same dataset using cross-validation, not on an independent cohort
• Unclear whether WDI generalises to different populations (age, metabolic phenotypes, ethnicities)
• No direct comparison of WDI's clinical utility against existing metrics in real-world decision-making
• SSPG itself, while accurate, is rarely ordered in routine care—the clinical relevance of predicting it well is untested